{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:07:53Z","timestamp":1790878073568,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00204-018-2341-6","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T09:25:32Z","timestamp":1540891532000},"page":"273-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Skin sensitization testing needs and data uses by US regulatory and research agencies"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4112-7484","authenticated-orcid":false,"given":"Judy","family":"Strickland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber B.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Aguila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-6995","authenticated-orcid":false,"given":"Surender","family":"Ahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evisabel","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dori","family":"Germolec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramallika","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi L.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-344X","authenticated-orcid":false,"given":"David M.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily N.","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakissa","family":"Sadrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Vukmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-3682","authenticated-orcid":false,"given":"Nicole","family":"Kleinstreuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"2341_CR1","volume-title":"F 2148-13, standard practice for evaluation of delayed contact hypersensitivity using the murine local lymph node assay (LLNA)","author":"ASTM","year":"2013","unstructured":"ASTM (2013) F 2148-13, standard practice for evaluation of delayed contact hypersensitivity using the murine local lymph node assay (LLNA). American Society for Testing and Materials, West Conshohocken"},{"issue":"2","key":"2341_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00204-017-2097-4","volume":"92","author":"S Casati","year":"2018","unstructured":"Casati S, Aschberger K, Barroso J, Casey W, Delgado I, Kim TS, Kleinstreuer N, Kojima H, Lee JK, Lowit A, Park HK, Regimbald-Krnel MJ, Strickland J, Whelan M, Yang Y, Zuang V (2018) Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the international cooperation on alternative test methods. Arch Toxicol 92(2):611\u2013617","journal-title":"Arch Toxicol"},{"issue":"1","key":"2341_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5487\/TR.2016.32.1.009","volume":"32","author":"W Casey","year":"2016","unstructured":"Casey W (2016) Advances in the development and validation of test methods in the United States. Toxicol Res 32(1):9\u201314","journal-title":"Toxicol Res"},{"key":"2341_CR4","unstructured":"CPSC (2012) Recommended procedures regarding the CPSC\u2019s policy on animal testing. \n                    https:\/\/www.cpsc.gov\/business--manufacturing\/testing-certification\/recommended-procedures-regarding-the-cpscs-policy-on-animal-testing\n                    \n                   Accessed 10 July 2018"},{"key":"2341_CR5","unstructured":"CPSC (2013) CPSC staff\u2019s strong sensitizer guidance document. \n                    https:\/\/www.cpsc.gov\/s3fs-public\/pdfs\/blk_pdf_strongsensitizerguidance.pdf\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR6","unstructured":"CPSC (2017a) Art materials. Labeling of hazardous art materials act. 16 CFR 1500.14(b)(8)"},{"key":"2341_CR7","unstructured":"CPSC (2017b) Certain statutory definitions interpreted, supplemented, or provided with alternatives. Federal Hazardous Substances Act. 16 CFR 1500.3(c)(5)"},{"key":"2341_CR8","unstructured":"CPSC (2017c) Definition of sensitizer. Federal Hazardous Substances Act. 16 CFR 1500.3(c)(5)(i)"},{"key":"2341_CR9","unstructured":"CPSC (2017d) Listing of \u201cstrong sensitizer\u201d substances. Federal Hazardous Substances Act. 16 CFR 1500.13"},{"key":"2341_CR10","unstructured":"CPSC (2017e) Significant potential for causing hypersensitivity. Federal Hazardous Substances Act. 16 CFR 1500.3(c)(5)(ii)"},{"key":"2341_CR11","unstructured":"CPSC (2017f) Statement on animal testing policy. Federal Hazardous Substances Act. 16 CFR 1500.232"},{"key":"2341_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.yrtph.2018.03.003","volume":"95","author":"AB Daniel","year":"2018","unstructured":"Daniel AB, Strickland J, Allen D, Casati S, Zuang V, Barroso J, Whelan M, Regimbald-Krnel MJ, Kojima H, Nishikawa A, Park HK, Lee JK, Kim TS, Delgado I, Rios L, Yang Y, Wang G, Kleinstreuer N (2018) International regulatory requirements for skin sensitization testing. Regul Toxicol Pharmacol 95:52\u201365","journal-title":"Regul Toxicol Pharmacol"},{"issue":"Pt 3","key":"2341_CR13","first-page":"385","volume":"45","author":"R \u00c1vila de","year":"2017","unstructured":"de \u00c1vila R, Teixeira G, Veloso D, Moreira L, Lima E, Valadares M (2017) In vitro assessment of skin sensitization, photosensitization and phototoxicity potential of commercial glyphosate-containing formulations. Toxicol In Vitro 45(Pt 3):385\u2013392","journal-title":"Toxicol In Vitro"},{"key":"2341_CR14","volume-title":"Guidance on information requirements and chemical safety assessment. Chapter R.7a: endpoint specific guidance (version 6.0)","author":"ECHA","year":"2017","unstructured":"ECHA (2017) Guidance on information requirements and chemical safety assessment. Chapter R.7a: endpoint specific guidance (version 6.0). European Chemicals Agency (ECHA), Helsinki"},{"key":"2341_CR15","volume-title":"Health effects test guidelines: OPPTS 870.2600\u2014skin sensitization","author":"EPA","year":"2003","unstructured":"EPA (2003) Health effects test guidelines: OPPTS 870.2600\u2014skin sensitization. US Environmental Protection Agency, Washington, DC"},{"key":"2341_CR16","volume-title":"Expansion of the traditional local lymph node assay for the assessment of dermal sensitization potential of end use pesticide products; and adoption of a \u201creduced\u201d protocol for the traditional LLNA (limit dose)","author":"EPA","year":"2011","unstructured":"EPA (2011) Expansion of the traditional local lymph node assay for the assessment of dermal sensitization potential of end use pesticide products; and adoption of a \u201creduced\u201d protocol for the traditional LLNA (limit dose). Office of Pesticide Programs, Washington, DC"},{"key":"2341_CR17","volume-title":"Guidance for waiving or bridging of mammalian acute toxicity tests for pesticides and pesticide products (acute oral, acute dermal, acute inhalation, primary eye, primary dermal, and dermal sensitization) (March 1, 2012)","author":"EPA","year":"2012","unstructured":"EPA (2012) Guidance for waiving or bridging of mammalian acute toxicity tests for pesticides and pesticide products (acute oral, acute dermal, acute inhalation, primary eye, primary dermal, and dermal sensitization) (March 1, 2012). Office of Pesticide Programs, Washington, DC"},{"key":"2341_CR18","volume-title":"Process for evaluating and implementing alternative approaches to traditional in vivo acute toxicity studies for FIFRA regulatory use","author":"EPA","year":"2016","unstructured":"EPA (2016) Process for evaluating and implementing alternative approaches to traditional in vivo acute toxicity studies for FIFRA regulatory use. Office of Pesticide Programs, Washington, DC"},{"key":"2341_CR19","unstructured":"EPA (2017) Summary of the Federal Insecticide, Fungicide, and Rodenticide Act. \n                    https:\/\/www.epa.gov\/laws-regulations\/summary-federal-insecticide-fungicide-and-rodenticide-act\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR20","volume-title":"Interim science policy: use of alternative approaches for skin sensitization as a replacement for laboratory animal testing","author":"EPA","year":"2018","unstructured":"EPA (2018a) Interim science policy: use of alternative approaches for skin sensitization as a replacement for laboratory animal testing. Office of Chemical Safety and Pollution Prevention, Office of Pesticide Programs, Office of Pollution Prevention and Toxics, Washington, DC"},{"key":"2341_CR21","volume-title":"Strategic plan to promote the development and implementation of alternative methods within the TSCA program","author":"EPA","year":"2018","unstructured":"EPA (2018b) Strategic plan to promote the development and implementation of alternative methods within the TSCA program. Office of Chemical Safety and Pollution Prevention, Washington, DC"},{"key":"2341_CR22","unstructured":"EPA (2018c) Strategic vision for adopting 21st century science methodologies. \n                    https:\/\/www.epa.gov\/pesticide-science-and-assessing-pesticide-risks\/strategic-vision-adopting-21st-century-science\n                    \n                   Accessed 10 July 2018"},{"issue":"42","key":"2341_CR23","first-page":"8912","volume":"40","author":"FDA","year":"1975","unstructured":"FDA (1975) Cosmetic products: warning statements\/package labels. Fed Reg 40(42):8912\u20138916","journal-title":"Fed Reg"},{"key":"2341_CR24","unstructured":"FDA (1999a) Guidance for industry\u2014skin irritation and sensitization testing of generic transdermal drug products (draft guidance). \n                    http:\/\/www.pharmanet.com.br\/pdf\/2887dft.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR25","unstructured":"FDA (1999b) Guidance for industry and FDA reviewers\/staff: premarket notification [501(k)] submissions for testing for skin sensitization to chemicals in natural rubber products. \n                    https:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/ucm073793.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR26","unstructured":"FDA (2002) Guidance for industry: immunotoxicology evaluation of investigational new drugs. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM079239.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR27","unstructured":"FDA (2008) Guidance for industry and FDA staff: medical glove guidance manual. \n                    https:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm428191.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR28","unstructured":"FDA (2016) Guidance for Industry and Food and Drug Administration staff: use of international standard ISO 10993-1, \u201cBiological evaluation of medical devices\u2014part 1: evaluation and testing within a risk management process. \n                    https:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/ucm348890.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR29","unstructured":"FDA (2018a) About the Center for Devices and Radiologic Health. \n                    https:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cdrh\/\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR30","unstructured":"FDA (2018b) About the Center for Drug Evaluation and Research. In. \n                    http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/default.htm\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR31","unstructured":"FDA (2018c) About the Center for Veterinary Medicine (CVM). In. \n                    https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofFoods\/CVM\/default.htm\n                    \n                  . Accessed 26 July 2018"},{"key":"2341_CR32","unstructured":"FDA (2018d) CBER vision & mission. In. \n                    https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CBER\/ucm122878.htm\n                    \n                  . Accessed 26 July 2018"},{"key":"2341_CR33","unstructured":"FDA (2018e) CFSAN\u2014what we do. \n                    https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofFoods\/CFSAN\/WhatWeDo\/default.htm\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR34","unstructured":"FDA (2018f) Product testing. \n                    https:\/\/www.fda.gov\/Cosmetics\/ScienceResearch\/ProductTesting\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR35","volume-title":"ISO 10993-10: Biological evaluation of medical devices\u2014part 10: tests for irritation and skin sensitization","author":"ISO","year":"2010","unstructured":"ISO (2010) ISO 10993-10: Biological evaluation of medical devices\u2014part 10: tests for irritation and skin sensitization. International Organization for Standardization, Geneva"},{"key":"2341_CR36","unstructured":"JRC (2017) EURL ECVAM recommendation on the use of non-animal approaches for skin sensitisation testing. Publications Office of the European Union, Luxembourg"},{"key":"2341_CR37","unstructured":"JRC (2018) Database on alternative methods (DB-ALM). \n                    https:\/\/eurl-ecvam.jrc.ec.europa.eu\/databases\/database-on-alternative-methods-db-alm\n                    \n                  . Accessed 26 July 2018"},{"issue":"5","key":"2341_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10408444.2018.1429386","volume":"48","author":"N Kleinstreuer","year":"2018","unstructured":"Kleinstreuer N, Hoffmann S, Alepee N et al (2018) Non-animal methods to predict skin sensitization (II): an assessment of defined approaches. Crit Rev Toxicol 48(5):359\u2013374","journal-title":"Crit Rev Toxicol"},{"key":"2341_CR39","volume-title":"Janeway\u2019s immunobiology","author":"K Murphy","year":"2012","unstructured":"Murphy K, Travers P, Walport M, Janeway C (2012) Janeway\u2019s immunobiology, 8th\u00a0edn. Garland Science, New York","edition":"8"},{"key":"2341_CR40","unstructured":"NIEHS (2018) A strategic roadmap for establishing new approaches to evaluate the safety of chemicals and medical products in the United States. \n                    https:\/\/www.ntp.niehs.nih.gov\/go\/natl-strategy\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR41","unstructured":"NIOSH (2009) A strategy for assigning new NIOSH skin notations. Current intelligence bulletin 61. DHHS (NIOSH) Publication No. 2009-147"},{"key":"2341_CR42","unstructured":"NTP (2018) Alternative methods accepted by US agencies. \n                    https:\/\/ntp.niehs.nih.gov\/pubhealth\/evalatm\/accept-methods\/index.html\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR43","doi-asserted-by":"publisher","DOI":"10.1787\/9789264070660-en","volume-title":"Test no. 406. Skin sensitisation. OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"1992","unstructured":"OECD (1992) Test no. 406. Skin sensitisation. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR44","doi-asserted-by":"publisher","DOI":"10.1787\/9789264071100-en","volume-title":"Test no. 429. Skin sensitisation: local lymph node assay. OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"2010","unstructured":"OECD (2010a) Test no. 429. Skin sensitisation: local lymph node assay. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR45","doi-asserted-by":"publisher","DOI":"10.1787\/9789264090972-en","volume-title":"Test no. 442A. Skin sensitization: local lymph node assay: DA. OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"2010","unstructured":"OECD (2010b) Test no. 442A. Skin sensitization: local lymph node assay: DA. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR46","doi-asserted-by":"publisher","DOI":"10.1787\/9789264090972-en","volume-title":"Test no. 442B. Skin sensitization: local lymph node assay: BrdU-ELISA. OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"2010","unstructured":"OECD (2010c) Test no. 442B. Skin sensitization: local lymph node assay: BrdU-ELISA. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR47","volume-title":"OECD series on testing and assessment no. 168. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 2: use of the AOP to develop chemical categories and integrated assessment and testing approaches","author":"OECD","year":"2012","unstructured":"OECD (2012a) OECD series on testing and assessment no. 168. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 2: use of the AOP to develop chemical categories and integrated assessment and testing approaches. OECD Publishing, Paris"},{"key":"2341_CR48","volume-title":"OECD series on testing and assessment no. 168. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 1: scientific assessment","author":"OECD","year":"2012","unstructured":"OECD (2012b) OECD series on testing and assessment no. 168. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 1: scientific assessment. OECD Publishing, Paris"},{"key":"2341_CR49","volume-title":"Test No. 442C. In chemico skin sensitization: direct peptide reactivity assay (DPRA). OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"2015","unstructured":"OECD (2015) Test no. 442C. In chemico skin sensitization: direct peptide reactivity assay (DPRA). OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR50","volume-title":"OECD series on testing and assessment no. 256. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation","author":"OECD","year":"2016","unstructured":"OECD (2016a) OECD series on testing and assessment no. 256. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation. OECD Publishing, Paris"},{"key":"2341_CR51","volume-title":"OECD series on testing and assessment no. 256. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation. Annex 1","author":"OECD","year":"2016","unstructured":"OECD (2016b) OECD series on testing and assessment no. 256. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation. Annex 1. OECD Publishing, Paris"},{"key":"2341_CR52","series-title":"OECD guidelines for the testing of chemicals, section 4: health effects","volume-title":"Test no. 442E. In vitro skin sensitisation. In vitro skin sensitisation assays addressing the key event on activation of dendritic cells on the adverse outcome pathway for skin sensitisation","author":"OECD","year":"2017","unstructured":"OECD (2017a) Test no. 442E. In vitro skin sensitisation. In vitro skin sensitisation assays addressing the key event on activation of dendritic cells on the adverse outcome pathway for skin sensitisation. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR53","unstructured":"OECD (2017b) Work plan for the test guidelines program (TGP) as of August 2017. \n                    http:\/\/www.oecd.org\/chemicalsafety\/testing\/TGP%20work%20plan_August%202017.pdf\n                    \n                  . Accessed 31 July 2018"},{"key":"2341_CR54","unstructured":"OECD (2018a) OECD guidelines for the testing of chemicals, section 4, health effects. \n                    https:\/\/www.oecd-ilibrary.org\/environment\/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788\n                    \n                  . Accessed 26 July 2018"},{"key":"2341_CR55","unstructured":"OECD (2018b) OECD test guidelines programme. \n                    http:\/\/www.oecd.org\/chemicalsafety\/testing\/oecd-guidelines-testing-chemicals-related-documents.htm\n                    \n                  . Accessed 26 July 2018"},{"key":"2341_CR56","volume-title":"Test no. 442D. In vitro skin sensitisation: ARE-Nrf2 luciferase test method. OECD guidelines for the testing of chemicals, section 4: health effects","author":"OECD","year":"2018","unstructured":"OECD (2018c) Test no. 442D. In vitro skin sensitisation: ARE-Nrf2 luciferase test method. OECD guidelines for the testing of chemicals, section 4: health effects. OECD Publishing, Paris"},{"key":"2341_CR57","unstructured":"OSHA (2016) Hazard communication: hazard classification guidance for manufacturers, importers, and employees. Occupational Safety and Health Administration, US Department of Labor Publication: OSHA 3844-02. \n                    https:\/\/www.osha.gov\/Publications\/OSHA3844.pdf\n                    \n                  . Accessed 10 July 2018"},{"key":"2341_CR58","unstructured":"OSHA (2017) Hazard communication. Occupational Safety and Health Act. 29 CFR 1910.1200"},{"issue":"1","key":"2341_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14573\/altex.1411011","volume":"32","author":"C Rovida","year":"2015","unstructured":"Rovida C, Alepee N, Api AM et al (2015) Integrated testing strategies (ITS) for safety assessment. ALTEX 32(1):25\u201340","journal-title":"ALTEX"},{"issue":"2","key":"2341_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.yrtph.2015.05.006","volume":"72","author":"R Settivari","year":"2015","unstructured":"Settivari R, Gehen S, Amado R, Visconti N, Boverhof D, Carney E (2015) Application of the KeratinoSens\u2122 assay for assessing the skin sensitization potential of agrochemical active ingredients and formulations. Regul Toxicol Pharmacol 72(2):350\u2013360","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"2341_CR61","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jat.3281","volume":"36","author":"J Strickland","year":"2016","unstructured":"Strickland J, Zang Q, Kleinstreuer N, Paris M, Lehmann DM, Choksi N, Matheson J, Jacobs A, Lowit A, Allen D, Casey W (2016) Integrated decision strategies for skin sensitization hazard. J Appl Toxicol 36(9):1150\u20131162","journal-title":"J Appl Toxicol"},{"key":"2341_CR62","volume-title":"Globally harmonized system of classification and labelling of chemicals, vol ST\/SG\/AC.10\/30\/Rev.3 3rd rev. edn","author":"UN","year":"2009","unstructured":"UN (2009) Globally harmonized system of classification and labelling of chemicals, vol ST\/SG\/AC.10\/30\/Rev.3, 3rd rev. edn. United Nations, New York"},{"issue":"1","key":"2341_CR63","first-page":"40","volume":"5","author":"B Varsho","year":"2017","unstructured":"Varsho B, Carathers M, Vij P, DeGeorge G (2017) The human cell line activation test (h-CLAT) for assessment of dermal sensitization potency of commercially available mixtures and the OECD proficiency chemicals. ALTEX Proc 5(1):40","journal-title":"ALTEX Proc"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-018-2341-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-018-2341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T19:04:34Z","timestamp":1572462274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-018-2341-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2341"],"URL":"https:\/\/doi.org\/10.1007\/s00204-018-2341-6","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"1 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}